

**CHAIR'S KEY ISSUES**  
**ISSUES FOR REFERRING/ESCALATING TO THE BOARD OF DIRECTORS**

<b>ORIGINATING COMMITTEE OR GROUP:</b>		Programmes Board	<b>DATE OF MEETING ISSUE RAISED:</b>	16 <sup>th</sup> March 2017	
<b>CHAIR:</b>		Martin Sinclair	<b>LEAD EXECUTIVE DIRECTOR:</b>	Chief Executive	
<b>Agenda Item No.</b>	<b>DETAILS OF ISSUE:</b>	<b>APPROVAL ESCALATION ASSURANCE</b>	<b>RISK REGISTER / BAF REFERENCE</b>	<b>PAPER ATTACHED</b> √	
2.1 Quality and Safety Improvement Programme	The Programme Board discussed the risks to the QSIP Programme, which included: delays in transfer to the wards from recovery; histology turnaround times; and an increased number of cancelled operations. It was noted that internal audit of the CQC programme had recommended that priority be given to the CQC 'must dos' (as opposed to equal priority to 'must dos' and 'should dos') and that the Trust self-assessment of the areas audited was consistently more positive than that of internal audit. Leads were being challenged to provide evidence of progress in their areas of responsibility and the Quality and Performance Committee is asked to ensure that it is assured regarding the stated progress	Escalation		Agenda item	
2.2 Workforce and leadership	The range of initiatives designed to improve staff engagement and well-being were discussed, but it was noted that these individual projects needed to be brought together in a cohesive programme, and that the Board needed to be assured of the actions taken in response to the staff survey findings.				
2.3 Clinical Transformation	The Programmes Board discussed progress with the elements of the Winter Plan, and the development of the broader Clinical Transformation programme which would include the response to the MTC review and options to decompress the RSCH site. The operational model would also be reviewed in Quarter 1. Good progress was being made with the Emergency Care Redevelopment and the Board would receive the OBC in March. The Board noted the importance of connectivity between the Programmes and of an overall clinical strategy to provide coherence to this work				

P

2.4 Financial Transformation	CIPs plans were being developed for 2017/18 with gross plans for £33m under development to achieve the plan of at least £19m.			
<b>DATE COMPLETED AND FORWARDED TO DIRECTOR OF CORPORATE AFFAIRS:</b>				

**PART B:**

<b>RECEIVING COMMITTEE:</b>	Board of Directors	<b>DATE OF MEETING ISSUE CONSIDERED:</b>	
<b>CHAIR:</b>		<b>LEAD EXECUTIVE DIRECTOR:</b>	
<b>Agenda Item No.</b>	<b>RECORD OF CONSIDERATION GIVEN / APPROVAL / RESPONSE / ACTION:</b>		
<b>DATE COMPLETED AND FORWARDED TO CHAIR OF ORIGINATING BOARD / COMMITTEE / TASK &amp; FINISH GROUP:</b>			